[引用][C] Quantification of [18 F] afatinib using PET/CT in NSCLC patients: a feasibility study
EA van de Stadt, M Yaqub, AA Lammertsma… - EJNMMI Research …, 2020 - jglobal.jst.go.jp
CA Cancer J Clin; Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries; F Bray, J Ferlay, I Soerjomataram, RL …
mortality worldwide for 36 cancers in 185 countries; F Bray, J Ferlay, I Soerjomataram, RL …
Quantification of [18F] afatinib using PET/CT in NSCLC patients: a feasibility study
EA van de Stadt, M Yaqub, AA Lammertsma… - EJNMMI …, 2020 - search.proquest.com
Methods [18 F] Afatinib PET scans were performed in 10 NSCLC patients. The first patient
was scanned for the purpose of dosimetry. Subsequent patients underwent a 20-min …
was scanned for the purpose of dosimetry. Subsequent patients underwent a 20-min …
Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study.
EA van de Stadt, M Yaqub… - EJNMMI …, 2020 - search.ebscohost.com
Introduction: Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
Quantification of [18F] afatinib using PET/CT in NSCLC patients: a feasibility study.
EA van de Stadt, M Yaqub, AA Lammertsma… - EJNMMI …, 2020 - europepmc.org
Methods [18 F] Afatinib PET scans were performed in 10 NSCLC patients. The first patient
was scanned for the purpose of dosimetry. Subsequent patients underwent a 20-min …
was scanned for the purpose of dosimetry. Subsequent patients underwent a 20-min …
[PDF][PDF] Quantification of [18 F] afatinib using PET/CT in NSCLC patients: a feasibility study
EA van de Stadt, M Yaqub, AA Lammertsma, AJ Poot… - 2020 - ejnmmires.springeropen.com
Introduction: Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
Quantification of [18F] afatinib using PET/CT in NSCLC patients: a feasibility study
EA van de Stadt, M Yaqub… - EJNMMI …, 2020 - researchinformation.amsterdamumc …
Introduction: Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
Quantification of [F-18] afatinib using PET/CT in NSCLC patients: a feasibility study
EA van de Stadt, M Yaqub… - EJNMMI …, 2020 - scholarlypublications …
Introduction: Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …